Lead Application: UTI


UTI is the most common bacterial infection in humans. It has no discernable geographic or ethnic basis. Those suffering from UTI are most likely to be women, children and the elderly, in that order. In the US, 15% of all community-prescribed antibiotics are for the treatment of UTI. Poorly-treated pre-natal UTI infections can cause complications for both mother and child.

Over 30% of US UTI infections are identified in ER settings, where patients present with fever and confusion. Patient treatment cost in US ER is 10 times that in primary care.

Current treatment

UTI today is generally treated by empiric antibiotics.

  • 50% of those treated don’t have a bacterial infection
  • 30% – 50% of those with a bacterial infection have resistance to the antibiotics they are prescribed

Empiric treatment exacerbates the growth of resistance

Spectromics diagnostic-guided treatment

Spectromics addresses current issues by testing patients individually for the presence of bacterial infection and antibiotic susceptibility/resistance.

The Spectromics low cost UTI test has clear economic as well as medical benefits.

  • Unnecessary treatment is avoided (where there is no infection)
  • The cost of multiple drugs is avoided (where there is resistance to the first antibiotic prescribed)
  • ER patients with UTI can be triaged at entry
  • Multiple physician appointments are avoided
  • Many hospital admissions are avoided
  • Infection of partners is avoided
  • Drug stewardship is improved

Key UTI metrics

Annual statistics US Global
UTI cases 8m 150m
Suspected UTIs 16m 300m
Primary care treatment cost $3.5b
Patients presenting to ER 2.5m
UTI treatment cost in ER $4.0b
Hospital admissions due to UTI 1m
UTI as a % total of community prescribed antibiotics 15%